Multiple Myeloma

clonoSEQ®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)[1]



Diagnostic workup

Consider baseline clone identification and storage of aspirate sample for future MRD testing by NGS.

Minimal residual disease (MRD) assessment:

- MRD testing is recommended at multiple times during and after treatment
- Consider MRD as indicated for prognostication after shared decision making with patient

Reference:

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.7.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed July 29, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

PM-US-cSEQ-0652